DELBERT M. BERGENSTAL, M.D., F.A.C.P.; ROY HERTZ, M.D., F.A.C.P.; MORTIMER B. LIPSETT, M.D.; RICHARD H. MOY, M.D.
Our approach to the chemotherapy of adrenocortical carcinoma is based upon the original observations of Nelson and Woodard.1 They observed that the oral administration to dogs of the insecticide, DDD, or Rothane, induced a selective necrosis of the zona fasciculata and zona reticularis of the adrenal cortex. Nichols and his associates2, 3 pursued this finding and demonstrated that adrenal cortical function was markedly diminished in dogs so treated. However, early attempts to apply this adrenocorticolytic effect in man were unsuccessful.4, 5, 6
Further exploration of the therapeutic potential of this compound was made possible by the observations that a contaminant
BERGENSTAL DM, HERTZ R, LIPSETT MB, et al. CHEMOTHERAPY OF ADRENOCORTICAL CANCER WITH o,p′DDD*. Ann Intern Med. 1960;53:672–682. doi: https://doi.org/10.7326/0003-4819-53-4-672
Download citation file:
Published: Ann Intern Med. 1960;53(4):672-682.
Adrenal Disorders, Endocrine and Metabolism, Endocrine Cancer, Hematology/Oncology.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use